Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors

Exclusion Criteria

• •1. Active autoimmune disease.
• •2. Patients considered to have a malignant T-cell clone.
• •3. Within 8 days after chemotherapy for lymphoma and within 14 days after chemotherapy for AML.
• •4. Tumor involvement in the bone marrow leading to hematopoietic suppression (neutrophils \<1.0×10\^9/L, HB\<70g/L, PLT\<50×10\^9/L).
• •5. HIV-positive patients and/or active HBV or HCV infection (as evidenced by positive HBV-DNA and HCV-RNA test records).
• •6. Patients with chronic respiratory diseases requiring continuous oxygen, or with significant past medical history of kidney, neurological, psychiatric, endocrine, metabolic, immune, hepatic, cardiovascular diseases.
• •7. Immunosuppressive treatment (such as cyclosporine, corticosteroids, ruxolitinib, JAK1/2 inhibitors, etc.) within the past 5 days.
• •8. Psychiatric disorders that would interfere with study participation.
• •9. Patients who have undergone allogeneic hematopoietic stem cell transplantation.
• •10. Consideration of allergy to Thymalfasin or Interleukin-2.
• •11. Any other condition that the researcher believes makes the patient unsuitable for this trial.